A QUALITY BY DESIGN DRIVEN DEVELOPMENT AND CHARACTERIZATION OF PALBOCICLIB-LOADED MESOPOROUS SILICA NANOPARTICLES IN HEPATOCELLULAR CARCINOMA THERAPY: ASSESSMENT OF CYTOTOXIC AND APOPTOTIC EFFECTS ON HEPG2 CELL LINE
DOI:
https://doi.org/10.22159/ijap.2026v18i3.57785Keywords:
Palbociclib, MSNs, MTTAssay, HepG2 cell line, CTABAbstract
Objective: Palbociclib has significant efficacy in Breast cancer as well as Hepatocellular Carcinoma therapy with its CDK4/6 inhibitory activity. Hence, the present work is aimed to formulate and characterize the Palbociclib loaded mesoporous silica nanoparticles to treat Hepatocellular Carcinoma.
Methods: Mesoporous Silica nanoparticles were produced through chemical synthesis utilizing tetra-ethyl-orthosilicate (TEOS), methanol (CH3OH), and deionized water with Ammonium hydroxide as a precipitating agent. The optimization of the drug-loaded Mesoporous Silica Nanoparticles (MSN) preparation was achieved using Box Behnken design (BBD). The resulting preparation underwent comprehensive characterization for Particle size, Entrapment Efficiency and zeta potential. The manufactured Nanoparticles were subjected to MTT assay study and Apoptosis study.
Results: The solubility of Palbociclib is low which was suitable to prepare MSNs by Solvent evaporation technology. The particle size of the preparation was 149-186.2nm, the entrapment efficiency is 66.9-78.8%.Cell viability found better results for the optimized Palbociclib mesoporous nanoparticles with the IC50 values of 45.04 µg/mL where Pure palbociclib showed IC50 70.12 µg/mL. MTT assay also demonstrated that it is better than Pure drug. As well as, based on results of the in vitro release study showed that MSNs could significantly improve drug stability as well as surface area.
Conclusion: Mesoporous Silica Nanoparticles have demonstrated effective ability against liver cancer cells based on the study of MTT assay and apoptosis. As well as it is found increase the solubility of drug substance ahead than pure drug, leading to enhanced absorption and as well effective against human hepatic cancer cells.
References
[1] SoppimathKS, AminabhaviTM, KulkarniAR, RudzinskiWE. Biodegradable polymeric nanoparticles as drug delivery devices.JControlRelease.2001Jan29;70(1-2):1-20.
[2] Rao, Jayprakash and KurtE. Geckeler. Polymer nanoparticles: Preparation techniques and size-controlparameters.”ProgressinPolymerScience36(2011):887-913.
[3] Yedi Herdiana, Nasrul Wathoni, Shaharum Shamsuddin, Muchtaridi, Scale-uppolymeric-based nanoparticles drug delivery systems: Development and challenges,OpenNano,Volume7,2022,100048,ISSN2352-9520.
[4] Balogh, J., Victor, D., 3rd, Asham, E. H., Burroughs, S. G., Boktour, M., Saharia, A., Li, X., Ghobrial, R. M., & Monsour, H. P., Jr (2016). Hepatocellular carcinoma: a review. Journal of hepatocellular carcinoma, 3, 41–53. https://doi.org/10.2147/JHC.S61146.
[5] Bruix, J., Gores, G. J., & Mazzaferro, V. (2014). Hepatocellular carcinoma: clinical frontiers and perspectives. Gut, 63(5), 844–855. https://doi.org/10.1136/gutjnl-2013-306627.
[6] Befele r, A. S., & Di Bisceglie, A. M. (2002). Hepatocellular carcinoma: diagnosis and treatment. Gastroenterology, 122(6), 1609–1619. https://doi.org/10.1053/gast.2002.33411.
[7] Scaria, B., Sood, S., Raad, C., Khanafer, J., Jayachandiran, R., Pupulin, A., Grewal, S., Okoko, M., Arora, M., Miles, L., & Pandey, S. (2020). Natural Health Products (NHP's) and Natural Compounds as Therapeutic Agents for the Treatment of Cancer; Mechanisms of Anti-Cancer Activity of Natural Compounds and Overall Trends. International journal of molecular sciences, 21(22), 8480. https://doi.org/10.3390/ijms21228480.
[8] Sang, R., Stratton, B., Engel, A., & Deng, W. (2021). Liposome technologies towards colorectal cancer therapeutics. Acta biomaterialia, 127, 24–40. https://doi.org/10.1016/j.actbio.2021.03.055.
[9] Motola-Kuba, D., Zamora-Valdés, D., Uribe, M., & Méndez-Sánchez, N. (2006). Hepatocellular carcinoma. An overview. Annals of hepatology, 5(1), 16–24. https://doi.org/10.1016/S1665-2681(19)32034-4.
[10] Zhang, F., Jia, Y., Zheng, X., Shao, D., Zhao, Y., Wang, Z., Dawulieti, J., Liu, W., Sun, M., Sun, W., Pan, Y., Cui, L., Wang, Y., He, K., Zhang, M., Li, J., Dong, W. F., & Chen, L. (2019). Janus nanocarrier-based co-delivery of doxorubicin and berberine weakens chemotherapy-exacerbated hepatocellular carcinoma recurrence. Acta biomaterialia, 100, 352–364. https://doi.org/10.1016/j.actbio.2019.09.034
[11] Zhao, R., Li, T., Zheng, G., Jiang, K., Fan, L., & Shao, J. (2017). Simultaneous inhibition of growth and metastasis of hepatocellular carcinoma by co-delivery of ursolic acid and sorafenib using lactobionic acid modified and pH-sensitive chitosan-conjugated mesoporous silica nanocomplex. Biomaterials, 143, 1–16. https://doi.org/10.1016/j.biomaterials.2017.07.030
[12] Morimoto, A., Kannari, M., Tsuchida, Y., Sasaki, S., Saito, C., Matsuta, T., Maeda, T., Akiyama, M., Nakamura, T., Sakaguchi, M., Nameki, N., Gonzalez, F. J., & Inoue, Y. (2017). An HNF4α-microRNA-194/192 signaling axis maintains hepatic cell function. The Journal of biological chemistry, 292(25), 10574–10585. https://doi.org/10.1074/jbc.M117.785592.
[13] García-Fernández, A., Vivo-Llorca, G., Sancho, M., García-Jareño, A. B., Ramírez-Jiménez, L., Barber-Cano, E., Murguía, J. R., Orzáez, M., Sancenón, F., & Martínez-Máñez, R. (2022). Nanodevices for the Efficient Codelivery of CRISPR-Cas9 Editing Machinery and an Entrapped Cargo: A Proposal for Dual Anti-Inflammatory Therapy. Pharmaceutics, 14(7), 1495. https://doi.org/10.3390/pharmaceutics14071495.
[14] Ugalde-Arbizu, M., Aguilera-Correa, J. J., Mediero, A., Esteban, J., Páez, P. L., San Sebastian, E., & Gómez-Ruiz, S. (2022). Hybrid Nanosystems Based on Nicotinate-Functionalized Mesoporous Silica and Silver Chloride Nanoparticles Loaded with Phenytoin for Preventing Pseudomonas aeruginosa Biofilm Development. Pharmaceuticals (Basel, Switzerland), 15(7), 884. https://doi.org/10.3390/ph15070884.
[15] Barbé, Christophe & Bartlett, J. & Kong, Linggen & Finnie, K. & Lin, H. & Larkin, M. & Calleja, S. & Bush, Alexandra & Calleja, Gerard. (2004). Silica Particles: A Novel Drug-Delivery System. Advanced Materials. 16. 1959-1966. 10.1002/adma.200400771.
[16] Brian G. Trewyn, Jennifer A. Nieweg, Yannan Zhao, Victor S.-Y. Lin, Biocompatible mesoporous silica nanoparticles with different morphologies for animal cell membrane penetration, Chemical Engineering Journal, Volume 137, Issue 1, 2008, Pages 23-29, ISSN 1385-8947, https://doi.org/10.1016/j.cej.2007.09.045.
[17] Lin, Yu Shen and Christy L. Haynes. “Synthesis and Characterization of Biocompatible and Size-Tunable Multifunctional Porous Silica Nanoparticles.” Chemistry of Materials 21 (2009): 3979-3986.
[18] Zhu, W., Chen, Z., Pan, Y., Dai, R., Wu, Y., Zhuang, Z., Wang, D., Peng, Q., Chen, C., & Li, Y. (2019). Functionalization of Hollow Nanomaterials for Catalytic Applications: Nanoreactor Construction. Advanced materials (Deerfield Beach, Fla.), 31(38), e1800426. https://doi.org/10.1002/adma.201800426.
[19] Du, X., Shi, B., Liang, J., Bi, J., Dai, S., & Qiao, S. Z. (2013). Developing functionalized dendrimer-like silica nanoparticles with hierarchical pores as advanced delivery nanocarriers. Advanced materials (Deerfield Beach, Fla.), 25(41), 5981–5985. https://doi.org/10.1002/adma.201302189.
[20] Ma, X., Zhao, Y., Ng, K. W., & Zhao, Y. (2013). Integrated hollow mesoporous silica nanoparticles for target drug/siRNA co-delivery. Chemistry (Weinheim an der Bergstrasse, Germany), 19(46), 15593–15603. https://doi.org/10.1002/chem.20130.
[21] Niu, D., Liu, Z., Li, Y., Luo, X., Zhang, J., Gong, J., et al. (2014). Monodispersed and ordered large pore mesoporous silica nanospheres with tunable pore structure for magnetic functionalization and gene delivery. Adv. Mater. 26, 4947–4953. https://doi: 10.1002/adma.201400815.
[22] Bernardos, A., Piacenza, E., Sancenón, F., Hamidi, M., Maleki, A., Turner, R. J., & Martínez-Máñez, R. (2019). Mesoporous Silica-Based Materials with Bactericidal Properties. Small (Weinheim an der Bergstrasse, Germany), 15(24), e1900669. https://doi.org/10.1002/smll.201900669.
[23] Phase II Study of Palbociclib (PD-0332991) + Letrozole vs Letrozole Alone in First-Line ER + /HER2- Advanced Breast Cancer Finn, R.S. et al
[24] https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207103Orig1s000SumR.pdf.
[25] Pazoki-Toroudi, H. R., Hesami, A., Vahidi, S., Sahebjam, F., Seifi, B., & Djahanguiri, B. (2003). The preventive effect of captopril or enalapril on reperfusion injury of the kidney of rats is independent of angiotensin II AT1 receptors. Fundamental & clinical pharmacology, 17(5), 595–598. https://doi.org/10.1046/j.1472-8206.2003.00188.x.
[26] Rocca A, Schirone A, Maltoni R, Bravaccini S, Cecconetto L, Farolfi A, Bronte G, Andreis D. Progress with palbociclib in breast cancer: latest evidence and clinical considerations. Ther Adv Med Oncol. 2017 Feb;9(2):83-105. doi: 10.1177/1758834016677961. Epub 2016 Nov 21. PMID: 28203301; PMCID: PMC5298405.
[27] Liu Y, Li Z, Zhang J, Liu W, Guan S, Zhan Y, Fang Y, Li Y, Deng H, Shen Z. DYNLL1 accelerates cell cycle via ILF2/CDK4 axis to promote hepatocellular carcinoma development and palbociclib sensitivity. Br J Cancer. 2024 Jul;131(2):243-257. doi: 10.1038/s41416-024-02719-2. Epub 2024 Jun 1. PMID: 38824222; PMCID: PMC11263598.
[28] Bollard J, Miguela V, Ruiz de Galarreta M, Venkatesh A, Bian CB, Roberto MP, Tovar V, Sia D, Molina-Sánchez P, Nguyen CB, Nakagawa S, Llovet JM, Hoshida Y, Lujambio A. Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma. Gut. 2017 Jul;66(7):1286-1296. doi: 10.1136/gutjnl-2016-312268. Epub 2016 Nov 14. PMID: 27849562; PMCID: PMC5512174.
[29] Digiacomo G, Fumarola C, La Monica S, Bonelli MA, Cretella D, Alfieri R, Cavazzoni A, Galetti M, Bertolini P, Missale G, Petronini PG. Simultaneous Combination of the CDK4/6 Inhibitor Palbociclib With Regorafenib Induces Enhanced Anti-tumor Effects in Hepatocarcinoma Cell Lines. Front Oncol. 2020 Sep 23;10:563249. doi: 10.3389/fonc.2020.563249. PMID: 33072590; PMCID: PMC7539564.
[30] Russo, M., Armetta, F., Riela, S., Chillura Martino, D., Lo Meo, P., and Noto, R. (2015). Silver nanoparticles stabilized by a polyaminocyclodextrin as catalysts for the reduction of nitroaromatic compounds. J. Mol. Catal. A Chem. 408, 250–261. doi: 10.1016/j.molcata.2015.07.031.
[31] Russo, M., Meli, A., Sutera, A., Gallo, G., Chillura Martino, D., Lo Meo, P., et al. (2016). Photosynthesized silver-polyaminocyclodextrin nanocomposites as promising antibacterial agents with improved activity. RSC Adv. 6, 40090–40099. doi: 10.1039/C6RA00042H.
[32] Qi, K., Cheng, B., Yu, J., and Ho, W. (2017). Review on the improvement of the photocatalytic and antibacterial activities of ZnO. J. Alloys Comp. 727, 792–820. doi: 10.1016/j.jallcom.2017.08.142.
[33] Qi, K., Li, Y., Xie, Y., Liu, S. -Y., Zheng, K., Chen, Z., et al. (2019). Ag loading enhanced photocatalytic activity of g-C3N4 porous nanosheets for decomposition of organic pollutants. Front. Chem. 7:91. doi: 10.3389/fchem.2019.00091.
[34] Qi, K., Xing, X., Zada, A., Li, M., and Wang, G. (2020). Transition metal doped ZnO nanoparticles with enhanced photocatalytic and antibacterial performances: experimental and DFT studies. Ceram. Int. 46, 1494–1502. doi: 10.1016/j.ceramint.2019.09.116.
[35] Cusimano, M. G., Ardizzone, F., Nasillo, G., Gallo, M., Sfriso, A., Chillura Martino, D., et al. (2020). Biogenic silver nanoparticles inhibit bacterial biofilm formation due to Ag+ release as determined by a novel phycoerythrin-based assay. Appl. Microbiol. Biotechnol. 104, 6325–6336. doi: 10.1007/s00253-020-10686-w.
[36] Yaqoob, A. A., Ahmad, H., Parveen, T., Ahmad, A., Oves, M., Ismail, I.M. I., et al. (2020). Recent advances in metal decorated nanomaterials and their various biological applications: a review. Front. Chem. 8:341. doi: 10.3389/fchem.2020.00341.
[37] Cavallaro, G., Lazzara, G., and Fakhrullin, R. (2018). Mesoporous inorganic nanoscale particles for drug adsorption and controlled release. Ther. Delivery 9, 287–301. doi: 10.4155/tde-2017-0120.
[38] Fidanza, M. R., and Caneva, G. (2019). Natural biocides for the conservation of stone cultural heritage: a review. J. Cult. Heritage 38, 271–286. doi: 10.1016/j.culher.2019.01.005.
[39] Popat, A., Liu, J., Hu, Q., Kennedy, M., Peters, B., Lu, G. Q., et al. (2012). Adsorption and release of biocides with mesoporous silica nanoparticles. Nanoscale 4, 970–975. doi: 10.1039/C2NR11691J.
[40] Ruggiero, L., Di Bartolomeo, E., Gasperi, T., Luisetto, I., Talone, A., Zurlo, F., et al. (2019). Silica nanosystems for active antifouling protection: nanocapsules and mesoporous nanoparticles in controlled release applications. J. Alloy Comp. 798, 144–148. doi: 10.1016/j.jallcom.2019.05.215.
[41] Böttcher, H., Jagota, C., Trepte, J., Kallies, K. H., and Haufe, H. (1999). Sol–gel composite films with controlled release of biocides. J. Control. Release. 60, 57–65. doi: 10.1016/S0168-3659(99)00053-X.
[42] Chan, A. C., Cadena, M. B., Townley, H. E., Fricker, M. D., and Thompson, I. P. (2017). Effective delivery of volatile biocides employing mesoporous silicates for treating biofilms. J. R. Soc. Interface 14:650. doi: 10.1098/rsif.2016.0650.
[43] Ruggiero, L., Crociani, L., Zendri, E., El Habra, N., and Guerriero, P. (2018). Incorporation of the zosteric sodium salt in silica nanocapsules: synthesis and characterization of new fillers for antifouling coatings. Appl. Surf. Sci. 439, 705–711. doi: 10.1016/j.apsusc.2017.12.228.
[44] https://fda.report/media/83664/quality-by-design-%28QbD%29-for-an-immediate-release.pdf.
[45] https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212436s005s006lbl.pdf.
[46] https://pubchem.ncbi.nlm.nih.gov/compound/5330286.
[47] Abdulkarim A, Altun Kavaklı A, Şara ON. The influence of surfactant type and calcination temperature on the formation of nickel oxide nanoparticles by chemical precipitation method. Journal of Thermal Analysis and Calorimetry. 2025 Oct;150(20):15937-51.
[48] Patel H, Lalan Ms. Qbd-Guided Design Of Nlc-Based Buccal Films Of A Phytoconstituent For Enhanced Chemoprevention. Int J App Pharm [Internet]. 2026 Jan. 7 [cited 2026 Jan. 31];18(1):242-9. Available from: https://journals.innovareacademics.in/index.php/ijap/article/view/56754.
[49] Yang, S. & Guo, Y.. (2014). Preparation of lomustine-iohexol thermosensitive compound liposomes and study on the in vitro release characteristics. Journal of Chemical and Pharmaceutical Research. 6. 408-415.
[50] Rajula, K. K., and Jisha mohanan. “Development of nanoparticles suspension for paediatric drug administration”. International Journal of Pharmacy and Pharmaceutical Sciences, vol. 14, no. 2, Feb. 2022, pp. 52-61, doi:10.22159/ijpps.2022v14i2.43529.
[51] Majumdar, S., Mondal, M., Bose, A. et al. Fabrication, design, and in vivo investigation of mesoporous silica-based docetaxel trihydrate nanoparticles for colonic drug delivery. Bull Natl Res Cent 47, 142 (2023). https://doi.org/10.1186/s42269-023-01117-7.
[52] Jia, L., Shen, J., Li, Z., Zhang, D., Zhang, Q., Liu, G., Zheng, D., & Tian, X. (2013). In vitro and in vivo evaluation of paclitaxel-loaded mesoporous silica nanoparticles with three pore sizes. International journal of pharmaceutics, 445(1-2), 12–19. https://doi.org/10.1016/j.ijpharm.2013.01.058.
[53] https://microbialnotes.com/mtt-assay-its-principle-and-protocol
[54] https://www.accessdata.fda.gov/scripts/cder/dissolution/dsp_SearchResults.cfm.
[55] Yang, G., Li, Z., Wu, F., Chen, M., Wang, R., Zhu, H., Li, Q., & Yuan, Y. (2020). Improving Solubility and Bioavailability of Breviscapine with Mesoporous Silica Nanoparticles Prepared Using Ultrasound-Assisted Solution-Enhanced Dispersion by Supercritical Fluids Method. International journal of nanomedicine, 15, 1661–1675. https://doi.org/10.2147/IJN.S238337.
[56] Gao, X., Zheng, Y., Ruan, X., Ji, H., Peng, L., Guo, D., & Jiang, S. (2018). Salinomycin induces primary chicken cardiomyocytes death via mitochondria mediated apoptosis. Chemico-biological interactions, 282, 45–54. https://doi.org/10.1016/j.cbi.2018.01.009.
[57] Edlich, A., Volz, P., Brodwolf, R., Unbehauen, M., Mundhenk, L., Gruber, A. D., Hedtrich, S., Haag, R., Alexiev, U., & Kleuser, B. (2018). Crosstalk between core-multishell nanocarriers for cutaneous drug delivery and antigen-presenting cells of the skin. Biomaterials, 162, 60–70. https://doi.org/10.1016/j.biomaterials.2018.01.058.
[58] Kuperkar K, Abezgauz L, Prasad K, Bahadur P. Formation and growth of micelles in dilute aqueous CTAB solutions in the presence of NaNO 3 and NaClO 3. Journal of surfactants and detergents. 2010 Jul;13:293-303.
[59] Ifijen IH, Ikhuoria EU, Aigbodion AI, Omorogbe SO. Impact of varying the concentration of tetraethyl-orthosilicate on the average particle diameter of monodisperse colloidal silica spheres. Chem Sci J. 2018;9(1):183-5.
[60] Dutta Gupta Y, Mackeyev Y, Krishnan S, Bhandary S. Mesoporous silica nanotechnology: promising advances in augmenting cancer theranostics. Cancer Nanotechnology. 2024 Dec;15(1):9
[61] Joseph D, Rodriguez RD, Verma A, Pousaneh E, Zahn DR, Lang H, Chandra S. Electrochemistry and surface-enhanced Raman spectroscopy of CTAB modulated interactions of magnetic nanoparticles with biomolecules. RSC advances. 2017;7(7):3628-34.
[62] Parsian M, Mutlu P, Taghavi Pourianazar N, Yalcin Azarkan S, Gunduz U. Investigation of the therapeutic effects of palbociclib conjugated magnetic nanoparticles on different types of breast cancer cell lines. Cellular and Molecular Bioengineering. 2023 Apr;16(2):143-57
[63] Zhang J, Han R, Chen W, Zhang W, Li Y, Ji Y, Chen L, Pan H, Yang X, Pan W, et al. Analysis of the Literature and Patents on Solid Dispersions from 1980 to 2015. Molecules. 2018; 23(7):1697. https://doi.org/10.3390/molecules23071697.
[64] Huang, Q., Zhang, L., Cheung, P.C., & Tan, X. (2006). Evaluation of sulfated α-glucans from Poria cocos mycelia as potential antitumor agent. Carbohydrate Polymers, 64, 337-344.
[65] Mohanty DL, Divya N, Zafar A, Warsi MH, Parida GR, Padhi P, Khalid M, Yasir M, Mujtaba MA. Development of etoricoxib-loaded mesoporous silica nanoparticles laden gel as vehicle for transdermal delivery: optimization, ex vivo permeation, histopathology, and in vivo anti-inflammatory study. Drug Development and Industrial Pharmacy. 2025 May 4;51(5):506-21.
[66] Alik Kumar L, Pattnaik G, Satapathy BS, Mohanty D, Prasanth PA, Dey S, Debata J. Preparation and Optimization of Gemcitabine Loaded PLGA Nanoparticle Using Box-Behnken Design for Targeting to Brain: In Vitro Characterization, Cytotoxicity and Apoptosis Study. Current Nanomaterials. 2024 Dec 1;9(4):324-38
[67] Liu, L., Liu, L., Trimarchi, J.R., Keefe, D.L., & Keefe, D.L. (1999). Thiol oxidation-induced embryonic cell death in mice is prevented by the antioxidant dithiothreitol. Biology of reproduction, 61 4, 1162-9.
[68] Koceva-Chyła, A., Jedrzejczak, M., Skierski, J., Kania, K., & Jóźwiak, Z. (2005). Mechanisms of induction of apoptosis by anthraquinone anticancer drugs aclarubicin and mitoxantrone in comparison with doxorubicin: relation to drug cytotoxicity and caspase-3 activation. Apoptosis: an international journal on programmed cell death, 10(6), 1497–1514. https://doi.org/10.1007/s10495-005-1540-9.
[69] Rogalska, A., Gajek, A., Szwed, M., Jóźwiak, Z., & Marczak, A. (2011). The role of reactive oxygen species in WP 631-induced death of human ovarian cancer cells: a comparison with the effect of doxorubicin. Toxicology in vitro: an international journal published in association with BIBRA, 25(8), 1712–1720. https://doi.org/10.1016/j.tiv.2011.08.009.
[70] Li, Xiujuan & Gao, Yan. (2020). Synergistically fabricated polymeric nanoparticles featuring dual drug delivery system to enhance the nursing care of cervical cancer. Process Biochemistry. 98. 254-261. 10.1016/j.procbio.2020.09.010.
[71] Shahmoradi SS, Salehzadeh A, Ranji N, Habibollahi H. Trigger of apoptosis in human liver cancer cell line (HepG2) by titanium dioxide nanoparticles functionalized by glutamine and conjugated with thiosemicarbazone. 3 Biotech. 2023 Jun;13(6):195.
Published
How to Cite
Issue
Section
Copyright (c) 2026 DHARMENDER GUVVALI, DIBYALOCHAN MOHANTY
This work is licensed under a Creative Commons Attribution 4.0 International License.